Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
Opinion|Videos|December 23, 2024

Early Intervention and Personalized Frontline Therapies in Multiple Myeloma

A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.

Episodes in this series

Video content above is prompted by the following:

  • How are you approaching patients with high-risk smoldering multiple myeloma, particularly in considering early intervention before traditional CRAB (hypercalcemia, renal dysfunction, anemia, bone disease) criteria are met?
  • What is your approach to personalizing first-line therapy selection among VRd (bortezomib, lenalidomide, and dexamethasone), KRd (carfilzomib, lenalidomide, and dexamethasone), and Dara-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone), considering the emerging quadruplet regimens?

Related Content